 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of [0m
[34mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"LORAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mLORAZEPAM[0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mLORAZEPAM[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"LORAZEPAM"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LORAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LORAZEPAM: openfda: brand_name         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: description: DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, [0m[1;31m7[0m[31m-chloro-[0m[1;31m5[0m[31m-[0m[1;31m([0m[31m o -chlorophenyl[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m3[0m[31m‑-dihydro-[0m[1;31m3[0m[31m-hydroxy-[0m[1;31m2[0m[31m H [0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m-benzodiazepin-[0m[1;31m2[0m[31m-one: It is a [0m
[31mnearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, or [0m[1;31m2[0m[31m mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, [0m
[31mmagnesium stearate, microcrystalline cellulose, and polacrilin potassium. LORAZEPAM: description: Chemical Structure         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: pharm_class_cs         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: spl_medguide: • Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including lorazepam tablets. These serious side [0m
[31meffects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. Call your healthcare provider or go to the nearest hospital emergency room right away if [0m
[31myou get any of these serious side effects. • You can develop an addiction even if you take lorazepam tablets exactly as prescribed by your healthcare provider. • Take lorazepam tablets exactly as your[0m
[31mhealthcare provider prescribed. • Do not share your lorazepam tablets with other people. • Keep lorazepam tablets in a safe place and away from children. • Physical dependence and withdrawal [0m
[31mreactions. Lorazepam tablets can cause physical dependence and withdrawal reactions. • Do not suddenly stop taking lorazepam tablets. LORAZEPAM: spl_medguide: Stopping lorazepam tablets suddenly can [0m
[31mcause serious and life-threatening side effects, including, unusual movements, responses or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing [0m
[31mthings that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. Call your healthcare provider or go to the nearest [0m
[31mhospital emergency room right away if you get any of these symptoms. • Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than [0m[1;31m12[0m[31m months, including [0m
[31manxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling [0m
[31mfeeling in your hands, arms, legs or feet, and ringing in your ears. • Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between [0m
[31mphysical dependence and drug addiction. LORAZEPAM: spl_medguide: • Do not take more lorazepam tablets than prescribed or take lorazepam tablets for longer than prescribed. What are lorazepam tablets? [0m
[31m• Lorazepam tablets are a prescription medicine used: • to treat anxiety disorders • for the short-term relief of the symptoms of anxiety or anxiety that can happen with symptoms of depression • [0m
[31mLorazepam tablets are a federal controlled substance [0m[1;31m([0m[31mCIV[0m[1;31m)[0m[31m because it contains lorazepam that can be abused or lead to dependence. Keep lorazepam tablets in a safe place to prevent misuse and abuse. [0m
[31mSelling or giving away lorazepam tablets may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.[0m
[31m• It is not known if lorazepam tablets are safe and effective for use in children less than [0m[1;31m12[0m[31m years of age. • It is not known if lorazepam tablets are safe and effective for use for longer than [0m[1;31m4[0m[31m [0m
[31mmonths. LORAZEPAM: spl_medguide: Do not take lorazepam tablets if you: • are allergic to lorazepam, other benzodiazepines, or any of the ingredients in lorazepam tablets. See the end of this [0m
[31mMedication Guide for a complete list of ingredients in lorazepam tablets. Before you take lorazepam tablets, tell your healthcare provider about all of your medical conditions, including if you: • [0m
[31mhave or have had depression, mood problems, or suicidal thoughts or behavior • have a history of drug or alcohol abuse or addiction • have lung disease or breathing problems [0m[1;31m([0m[31msuch as COPD, sleep apnea[0m
[31msyndrome[0m[1;31m)[0m[31m • have liver or kidney problems • have or have had seizures • are pregnant or plan to become pregnant. • Taking lorazepam tablets late in pregnancy may cause your baby to have symptoms of [0m
[31msedation [0m[1;31m([0m[31mbreathing problems, sluggishness, low muscle tone[0m[1;31m)[0m[31m, and/or withdrawal symptoms [0m[1;31m([0m[31mjitteriness, irritability, restlessness, shaking, excessive crying, feeding problems[0m[1;31m)[0m[31m. LORAZEPAM: [0m
[31mspl_medguide: • Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with lorazepam tablets. • There is a pregnancy registry for women who take [0m
[31mlorazepam tablets during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with lorazepam tablets, talk to[0m
[31myour healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting [0m
[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m • are breastfeeding or plan to breastfeed. Lorazepam passes into your breast milk. • Breastfeeding during treatment with lorazepam tablets may cause [0m
[31myour baby to have sleepiness, feeding problems, and decreased weight gain. • Talk to your healthcare provider about the best way to feed your baby if you take lorazepam tablets. LORAZEPAM: [0m
[31mspl_medguide: Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking lorazepam tablets with [0m
[31mcertain other medicines can cause side effects or affect how well lorazepam tablets or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. How [0m
[31mshould I take lorazepam tablets? • Take lorazepam tablets exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you how much lorazepam tablets to take and when [0m
[31mto take it. • If you take too much lorazepam tablets, call your healthcare provider or go to the nearest hospital emergency room right away. What are the possible side effects of lorazepam tablets? [0m
[31mLorazepam tablets may cause serious side effects, including: • See “What is the most important information I should know about lorazepam tablets?” • Lorazepam tablets can make you sleepy or dizzy and [0m
[31mcan slow your thinking and motor skills. LORAZEPAM: spl_medguide: • Do not drive, operate heavy machinery, or do other dangerous activities until you know how lorazepam tablets affects you. • Do not [0m
[31mdrink alcohol or take other drugs that may make you sleepy or dizzy while taking lorazepam tablets without first talking to your healthcare provider. When taken with alcohol or drugs that cause [0m
[31msleepiness or dizziness, lorazepam tablets may make your sleepiness or dizziness much worse. • Depression. Pre-existing depression may emerge or worsen during use of benzodiazepines including [0m
[31mlorazepam tablets. The most common side effects of lorazepam tablets include: • sedation • dizziness • weakness • unsteadiness These are not all the possible side effects of lorazepam tablets. Call [0m
[31myour doctor for medical advice about side effects. You may report side effects to FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How should I store lorazepam tablets? LORAZEPAM: spl_medguide: • Store lorazepam tablets in a [0m
[31mtightly closed container at room temperature between [0m[1;31m20[0m[31m° to [0m[1;31m25[0m[31m°C [0m[1;31m([0m[1;31m68[0m[31m° to [0m[1;31m77[0m[31m°F[0m[1;31m)[0m[31m. • Keep lorazepam tablets and all medicines out of the reach of children. General information about the safe and [0m
[31meffective use of lorazepam tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lorazepam tablets for a condition for which it was not [0m
[31mprescribed. Do not give lorazepam tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about[0m
[31mlorazepam tablets that is written for health professionals. What are the ingredients in lorazepam tablets? Active ingredient: lorazepam Inactive ingredients: anhydrous lactose, magnesium stearate, [0m
[31mmicrocrystalline cellulose, and polacrilin potassium. LORAZEPAM: spl_medguide: Distributed by: Aurobindo Pharma USA, Inc. [0m[1;31m279[0m[31m Princeton-Hightstown Road East Windsor, NJ [0m[1;31m08520[0m[31m Manufactured by: [0m
[31mAurobindo Pharma Limited Hyderabad-[0m[1;31m500[0m[31m [0m[1;31m032[0m[31m, India For more information, call Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m. This Medication Guide has been approved by the U.S. Food and Drug [0m
[31mAdministration. Repackaged by Preferred Pharmaceuticals, Inc. LORAZEPAM: spl_medguide: Revised: [0m[1;31m06[0m[31m/[0m[1;31m2023[0m[31m         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: drug_abuse_and_dependence: The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, [0m
[31mseizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use [0m[1;31m([0m[31mespecially benzodiazepines with other CNS depressants such as opioids and alcohol[0m[1;31m)[0m[31m. Dependence [0m
[31mPhysical Dependence Lorazepam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug [0m
[31muse, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or [0m
[31madministration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal [0m
[31madverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages [0m[1;31m([0m[31mi. LORAZEPAM: drug_abuse_and_dependence: ., higher and/or more frequent doses[0m[1;31m)[0m[31m [0m
[31mand those who have had longer durations of use [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions [0m[1;31m)[0m[31m. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce [0m
[31mthe dosage [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of lorazepam and WARNINGS [0m[1;31m)[0m[31m. Acute Withdrawal Signs and Symptoms Acute withdrawal signs and symptoms associated with [0m
[31mbenzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions [0m[1;31m([0m[31me.g., [0m
[31mnausea, vomiting, diarrhea, weight loss, decreased appetite[0m[1;31m)[0m[31m, headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, [0m
[31mrestlessness, tachycardia, and tremor. LORAZEPAM: drug_abuse_and_dependence: More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, [0m
[31mconvulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures and suicidality. Protracted Withdrawal Syndrome Protracted withdrawal syndrome associated with benzodiazepines is [0m
[31mcharacterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms [0m[1;31m([0m[31me.g., weakness, tremor, muscle twitches[0m[1;31m)[0m[31m, paresthesia, and tinnitus that persists beyond [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m weeks[0m
[31mafter initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than [0m[1;31m12[0m[31m months. As a result, there may be difficulty in differentiating withdrawal symptoms from [0m
[31mpotential re‑-emergence or continuation of symptoms for which the benzodiazepine was being used. Tolerance Tolerance to lorazepam may develop from continued therapy. LORAZEPAM: [0m
[31mdrug_abuse_and_dependence: Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration [0m[1;31m([0m[31mi.e., a higher dose of a drug is required to produce the same[0m
[31meffect that was once obtained at a lower dose[0m[1;31m)[0m[31m. Tolerance to the therapeutic effect of lorazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive [0m
[31mimpairments caused by benzodiazepines.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: precautions: However, use of lorazepam for prolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper GI disease. [0m
[31mSafety and effectiveness of lorazepam in children of less than [0m[1;31m12[0m[31m years have not been established. Information for Patients Advise the patient to read the FDA-approved patient labeling [0m[1;31m([0m[31m Medication [0m
[31mGuide [0m[1;31m)[0m[31m. Risks from Concomitant Use with Opioids Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when lorazepam is used with opioids and [0m
[31mnot to use such drugs concomitantly unless supervised by a healthcare provider. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been [0m
[31mdetermined [0m[1;31m([0m[31msee WARNINGS: Risks from Concomitant Use of Opioids and PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Abuse, Misuse, and Addiction Inform patients that the use of lorazepam [0m
[31meven at recommended doses, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications [0m[1;31m([0m[31me.g., opioid [0m
[31manalgesics[0m[1;31m)[0m[31m, alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or [0m
[31msymptoms; and on the proper disposal of unused drug [0m[1;31m([0m[31msee WARNINGS: Abuse Misuse, and Addiction and DRUG ABUSE AND DEPENDENCE [0m[1;31m)[0m[31m. Withdrawal Reactions Inform patients that the continued use of lorazepam[0m
[31mmay lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of lorazepam may precipitate acute withdrawal reactions, which can be life-threatening.[0m
[31mLORAZEPAM: precautions: Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than [0m[1;31m12[0m[31m [0m
[31mmonths. Instruct patients that discontinuation or dosage reduction of lorazepam may require a slow taper [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE [0m[1;31m)[0m[31m. Pregnancy [0m
[31mAdvise pregnant females that use of lorazepam late in pregnancy can result in sedation [0m[1;31m([0m[31mrespiratory depression, lethargy, hypotonia[0m[1;31m)[0m[31m and/or withdrawal symptoms [0m[1;31m([0m[31mhyperreflexia, irritability, [0m
[31mrestlessness, tremors, inconsolable crying, and feeding difficulties[0m[1;31m)[0m[31m in newborns [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. Instruct patients to inform [0m
[31mtheir healthcare provider if they are pregnant. LORAZEPAM: precautions: Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam [0m
[31mduring pregnancy [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy [0m[1;31m)[0m[31m. Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using [0m
[31mlorazepam to monitor infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs [0m[1;31m([0m[31msee PRECAUTIONS: Nursing Mothers [0m[1;31m)[0m[31m. Essential [0m
[31mLaboratory Tests Some patients on lorazepam have developed leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are [0m
[31mrecommended for patients on long-term therapy. Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different [0m
[31mreceptor sites in the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. LORAZEPAM: precautions: When benzodiazepines and opioids [0m
[31mare combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and [0m
[31mmonitor patients closely for respiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such [0m
[31mas alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine[0m
[31mand lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased [0m
[31mplasma concentrations and reduced clearance of lorazepam. LORAZEPAM: precautions: Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration [0m
[31mof lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by [0m
[31mapproximately [0m[1;31m50[0m[31m% when coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline[0m
[31mmay reduce the sedative effects of benzodiazepines, including lorazepam. Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with lorazepam. [0m
[31mNo studies regarding mutagenesis have been performed. LORAZEPAM: pregnancy: Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to [0m
[31mpsychiatric medications, including lorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at [0m
[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting online at [0m[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience [0m
[31msymptoms of sedation and/or neonatal withdrawal [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant [0m
[31mwomen exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data[0m[1;31m)[0m[31m . The background risk of major birth defects and miscarriage for the [0m
[31mindicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. LORAZEPAM: pregnancy: general population, the estimated risk of [0m
[31mmajor birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the[0m
[31mplacenta and may produce respiratory depression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, [0m
[31mhypotonia, and feeding problems. Monitor neonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal [0m
[31mSyndrome [0m[1;31m)[0m[31m. Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects.    [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: clinical_pharmacology: CLINICAL PHARMACOLOGY Studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no[0m
[31mappreciable effect on the respiratory or cardiovascular systems. Lorazepam is readily absorbed with an absolute bioavailability of [0m[1;31m90[0m[31m%. Peak concentrations in plasma occur approximately [0m[1;31m2[0m[31m hours [0m
[31mfollowing administration. The peak plasma level of lorazepam from a [0m[1;31m2[0m[31m mg dose is approximately [0m[1;31m20[0m[31m ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about [0m[1;31m12[0m[31m hours and for its [0m
[31mmajor metabolite, lorazepam glucuronide, about [0m[1;31m18[0m[31m hours. At clinically relevant concentrations, lorazepam is approximately [0m[1;31m85[0m[31m% bound to plasma proteins. Lorazepam is rapidly conjugated at its [0m
[1;31m3[0m[31m-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m activity in animals. LORAZEPAM: [0m
[31mclinical_pharmacology: The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to [0m[1;31m6[0m[31m months. Studies comparing young [0m
[31mand elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of [0m[1;31m1.5[0m[31m to [0m[1;31m3[0m[31m mg of [0m
[31mlorazepam Injection, mean total body clearance of lorazepam decreased by [0m[1;31m20[0m[31m% in [0m[1;31m15[0m[31m elderly subjects of [0m[1;31m60[0m[31m to [0m[1;31m84[0m[31m years of age compared to that in [0m[1;31m15[0m[31m younger subjects of [0m[1;31m19[0m[31m to [0m[1;31m38[0m[31m years of age.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: overdosage: OVERDOSAGE Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can [0m
[31minclude drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions [0m[1;31m([0m[31mincluding agitation, irritability, [0m
[31mimpulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness[0m[1;31m)[0m[31m may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of [0m
[31mbenzodiazepines in combination with other CNS depressants [0m[1;31m([0m[31mincluding alcohol and opioids[0m[1;31m)[0m[31m may be fatal [0m[1;31m([0m[31msee WARNINGS: Abuse, Misuse , and Addiction [0m[1;31m)[0m[31m. Markedly abnormal [0m[1;31m([0m[31mlowered or elevated[0m[1;31m)[0m[31m blood [0m
[31mpressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage. LORAZEPAM: overdosage: In managing benzodiazepine overdosage, employ [0m
[31mgeneral supportive measures, including intravenous fluids and airway management. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the [0m
[31msedative effects of benzodiazepines in the management of benzodiazepine overdosage, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage [0m
[31mwith drugs that increase seizure risk [0m[1;31m([0m[31me.g., tricyclic and tetracyclic antidepressants[0m[1;31m)[0m[31m and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with [0m
[31mflumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition [0m[1;31m([0m[31me.g., [0m
[31mstatus epilepticus[0m[1;31m)[0m[31m. LORAZEPAM: overdosage: If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdosage. [0m
[31mSee the flumazenil injection Prescribing Information. Consider contacting the Poison Help line [0m[1;31m([0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m222[0m[31m-[0m[1;31m1222[0m[1;31m)[0m[31m or a medical toxicologist for additional overdosage management recommendations.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: drug_interactions: Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites [0m
[31min the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for [0m
[31mbenzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for [0m
[31mrespiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, [0m
[31mantipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. LORAZEPAM: drug_interactions: Concomitant use of [0m
[31mclozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in [0m
[31mincreased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam [0m
[31mwith probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% [0m
[31mwhen coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the [0m
[31msedative effects of benzodiazepines, including lorazepam.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: spl_product_data_elements: Lorazepam Lorazepam LORAZEPAM LORAZEPAM ANHYDROUS LACTOSE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POLACRILIN POTASSIUM White to off white [0m
[31mFlat-faced beveled edge U33         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: how_supplied: HOW SUPPLIED Lorazepam Tablets, USP are available in the following dosage strengths: [0m[1;31m1[0m[31m mg, white to off-white, round, flat-faced beveled edge tablets debossed with [0m
[31m‘U33’ on one side and bisect on the other side. Bottles of [0m[1;31m30[0m[31m NDC [0m[1;31m68788[0m[31m-[0m[1;31m7428[0m[31m-[0m[1;31m03[0m[31m Bottles of [0m[1;31m60[0m[31m NDC [0m[1;31m68788[0m[31m-[0m[1;31m7428[0m[31m-[0m[1;31m06[0m[31m Bottles of [0m[1;31m90[0m[31m NDC [0m[1;31m68788[0m[31m-[0m[1;31m7428[0m[31m-[0m[1;31m09[0m[31m Bottles of [0m[1;31m100[0m[31m NDC [0m[1;31m68788[0m[31m-[0m[1;31m7428[0m[31m-[0m[1;31m01[0m[31m Bottles of [0m[1;31m120[0m[31m NDC [0m
[1;31m68788[0m[31m-[0m[1;31m7428[0m[31m-[0m[1;31m08[0m[31m Keep bottles tightly closed. Keep out of reach of children. Store at [0m[1;31m20[0m[31m° to [0m[1;31m25[0m[31m°C [0m[1;31m([0m[1;31m68[0m[31m° to [0m[1;31m77[0m[31m°F[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee USP Controlled Room Temperature[0m[1;31m][0m[31m. Dispense in a tight, light-resistant container as [0m
[31mdescribed in the USP. Dispense with Medication Guide available at: www.aurobindousa. LORAZEPAM: how_supplied: [0m[31m/[0m[31mmedication-guides[0m[31m Distributed by: Aurobindo Pharma USA, Inc. [0m[1;31m279[0m[31m Princeton-Hightstown [0m
[31mRoad East Windsor, NJ [0m[1;31m08520[0m[31m Manufactured by: Aurobindo Pharma Limited Hyderabad-[0m[1;31m500[0m[31m [0m[1;31m032[0m[31m, India Revised: [0m[1;31m06[0m[31m/[0m[1;31m2023[0m[31m Repackaged by Preferred Pharmaceuticals, Inc. Dispense with Medication Guide available [0m
[31mat: www.aurobindousa. LORAZEPAM: how_supplied: [0m[31m/[0m[31mmedication-guides[0m[31m         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: generic_name         [0m
[31mSOURCE:LORAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Lorazepam is an antianxiety agent that belongs to the class of drugs known as benzodiazepines. It is used to treat anxiety disorders and for the short-term relief of symptoms of anxiety or [0m
[32manxiety associated with depression. Lorazepam is available in tablet form for oral administration, with dosages of [0m[1;32m0.5[0m[32m mg, [0m[1;32m1[0m[32m mg, or [0m[1;32m2[0m[32m mg. The medication can cause serious side effects, including coma [0m
[32mand death, particularly if abused or misused. It has the potential to cause physical dependence and withdrawal reactions, and should not be stopped suddenly due to the risk of serious and [0m
[32mlife-threatening side effects. Lorazepam is a controlled substance due to its potential for abuse and dependence. It is not known if lorazepam is safe and effective for use in children under [0m[1;32m12[0m[32m years [0m
[32mof age or for use longer than [0m[1;32m4[0m[32m months. The medication can interact with other drugs, especially opioids, leading to increased risk of respiratory depression and sedation. It is also contraindicated [0m
[32min patients with certain medical conditions and should be used with caution in elderly patients and those with a history of drug or alcohol abuse or addiction.[0m

[32mSOURCE: LORAZEPAM label[0m
[32mEXTRACT_START_END: DESCRIPTION Lorazepam USP, an antianxiety agent [0m[32m...[0m[32m for a complete list of ingredients in lorazepam tablets.[0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Lorazepam is an antianxiety agent that [0m
[34mbelongs to the class of drugs known as benzodiazepines. It is used to treat anxiety disorders and for the short-term relief of symptoms of anxiety or anxiety associated with depression. Lorazepam is [0m
[34mavailable in tablet form for oral administration, with dosages of [0m[1;34m0.5[0m[34m mg, [0m[1;34m1[0m[34m mg, or [0m[1;34m2[0m[34m mg. The medication can cause serious side effects, including coma and death, particularly if abused or misused. It [0m
[34mhas the potential to cause physical dependence and withdrawal reactions, and should not be stopped suddenly due to the risk of serious and life-threatening side effects. Lorazepam is a controlled [0m
[34msubstance due to its potential for abuse and dependence. It is not known if lorazepam is safe and effective for use in children under [0m[1;34m12[0m[34m years of age or for use longer than [0m[1;34m4[0m[34m months. The medication [0m
[34mcan interact with other drugs, especially opioids, leading to increased risk of respiratory depression and sedation. It is also contraindicated in patients with certain medical conditions and should [0m
[34mbe used with caution in elderly patients and those with a history of drug or alcohol abuse or addiction.[0m

[34mSOURCE: LORAZEPAM label[0m
[34mEXTRACT_START_END: DESCRIPTION Lorazepam USP, an antianxiety agent [0m[34m...[0m[34m for a complete list of ingredients in lorazepam tablets.[0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler about the effects of Lorazepam."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information about Lorazepam, including its use, potential for abuse, dependence, and serious side effects such as coma and death, particularly if misused or abused. However,[0m
[32mthe information did not specifically address the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Since the FDA label data provided by FDAHandler does not mention the effect of Lorazepam on mortality after myocardial infarction, I cannot determine whether Lorazepam increases or decreases [0m
[32mthis risk based on the available FDA label data."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LORAZEPAM increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler about the effects of Lorazepam."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information about Lorazepam, including its use, potential for abuse, dependence, and serious side effects such as coma and death, particularly if misused or abused. However,[0m
[34mthe information did not specifically address the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Since the FDA label data provided by FDAHandler does not mention the effect of Lorazepam on mortality after myocardial infarction, I cannot determine whether Lorazepam increases or decreases [0m
[34mthis risk based on the available FDA label data."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LORAZEPAM increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler about the effects of Lorazepam.[0m
[1;31m2[0m[31m. FDAHandler provided information about Lorazepam, including its use, potential for abuse, dependence, and serious side effects such as coma and death, particularly if misused or abused. However, the[0m
[31minformation did not specifically address the risk of mortality after myocardial infarction.[0m
[1;31m3[0m[31m. Since the FDA label data provided by FDAHandler does not mention the effect of Lorazepam on mortality after myocardial infarction, I cannot determine whether Lorazepam increases or decreases this [0m
[31mrisk based on the available FDA label data.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label data provided by FDAHandler does not mention the effect of Lorazepam on mortality after myocardial infarction. Therefore, I cannot determine whether Lorazepam increases or decreases this[0m
[32mrisk based on the available FDA label data.[0m
